Title : Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.

Pub. Date : 2021 Dec

PMID : 34521277






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the Phase III ICARIA-MM study (NCT02990338), the addition of the anti-CD38 monoclonal antibody isatuximab to pomalidomide and dexamethasone led to increased progression-free survival and improved response rates in patients with relapsed/refractory multiple myeloma. Dexamethasone CD38 molecule Homo sapiens